RU2020137883A - Композиции, содержащие 15-hepe, и способы их применения - Google Patents
Композиции, содержащие 15-hepe, и способы их применения Download PDFInfo
- Publication number
- RU2020137883A RU2020137883A RU2020137883A RU2020137883A RU2020137883A RU 2020137883 A RU2020137883 A RU 2020137883A RU 2020137883 A RU2020137883 A RU 2020137883A RU 2020137883 A RU2020137883 A RU 2020137883A RU 2020137883 A RU2020137883 A RU 2020137883A
- Authority
- RU
- Russia
- Prior art keywords
- hepe
- composition
- pharmaceutically acceptable
- acceptable derivative
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 15
- WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 title claims 13
- 238000000034 method Methods 0.000 title claims 12
- 150000003839 salts Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 210000001789 adipocyte Anatomy 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 230000035558 fertility Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000902 placebo Substances 0.000 claims 1
- 229940068196 placebo Drugs 0.000 claims 1
- 125000005457 triglyceride group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269280P | 2015-12-18 | 2015-12-18 | |
| US62/269,280 | 2015-12-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018126361A Division RU2737089C2 (ru) | 2015-12-18 | 2016-12-19 | Композиции, содержащие 15-hepe, и способы их применения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020137883A true RU2020137883A (ru) | 2020-12-03 |
Family
ID=57995240
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020137883A RU2020137883A (ru) | 2015-12-18 | 2016-12-19 | Композиции, содержащие 15-hepe, и способы их применения |
| RU2018126361A RU2737089C2 (ru) | 2015-12-18 | 2016-12-19 | Композиции, содержащие 15-hepe, и способы их применения |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018126361A RU2737089C2 (ru) | 2015-12-18 | 2016-12-19 | Композиции, содержащие 15-hepe, и способы их применения |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9855238B2 (https=) |
| EP (2) | EP4218736A3 (https=) |
| JP (4) | JP2018537513A (https=) |
| KR (6) | KR20230047501A (https=) |
| CN (2) | CN108697680A (https=) |
| AR (2) | AR107143A1 (https=) |
| AU (4) | AU2016370626B2 (https=) |
| BR (1) | BR122023026625A2 (https=) |
| CA (2) | CA3129008A1 (https=) |
| ES (1) | ES2948444T3 (https=) |
| IL (3) | IL294736A (https=) |
| MX (2) | MX379262B (https=) |
| NZ (1) | NZ744323A (https=) |
| PH (1) | PH12018501279A1 (https=) |
| RU (2) | RU2020137883A (https=) |
| SG (1) | SG11201805149XA (https=) |
| WO (1) | WO2017103671A1 (https=) |
| ZA (2) | ZA201804779B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| JP2016538288A (ja) | 2013-11-15 | 2016-12-08 | ディグニティ サイエンシス リミテッド | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
| MA41120A (fr) | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| MA47141A (fr) | 2015-05-13 | 2019-11-06 | Ds Biopharma Ltd | Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation |
| ES2851525T3 (es) | 2015-07-21 | 2021-09-07 | Afimmune Ltd | Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia |
| CA3129008A1 (en) * | 2015-12-18 | 2017-06-22 | Afimmune Limited | Compositions comprising 15-hepe and methods of using the same |
| CN113116878A (zh) * | 2020-01-10 | 2021-07-16 | 南京大学 | 15s-hepe用于增强t细胞介导的肿瘤免疫治疗的新用途 |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| US11622495B2 (en) | 2021-06-01 | 2023-04-11 | Gint Co., Ltd. | Method of automatically combining farm vehicle and work machine and farm vehicle |
| CN113855659B (zh) * | 2021-11-24 | 2022-12-23 | 中国人民解放军东部战区总医院 | 12-hepe或其药学上可接受的脂肪酸改善精子发生障碍的应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05186342A (ja) * | 1992-01-10 | 1993-07-27 | Fujirebio Inc | 免疫調節作用を併せもつ抗炎症剤 |
| GB9301446D0 (en) | 1993-01-26 | 1993-03-17 | Scotia Holdings Plc | Internal radiation damage |
| AU683027B2 (en) | 1993-01-27 | 1997-10-30 | Scotia Holdings Plc | Triglycerides |
| JPH09505562A (ja) | 1993-10-01 | 1997-06-03 | アール．ピー．シェーラー コーポレイション | 香料を小分けして提供する方法および組成物 |
| GB9715444D0 (en) | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| JP2000191525A (ja) | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
| EP1762557B1 (en) | 2000-02-16 | 2011-04-06 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
| US20020188024A1 (en) | 2000-08-23 | 2002-12-12 | Chilton Floyd H. | Fatty acid-containing emulsion with increased bioavailability |
| US20040043013A1 (en) | 2000-12-28 | 2004-03-04 | Mccleary Edward Larry | Metabolic uncoupling therapy |
| ATE291910T1 (de) | 2001-05-30 | 2005-04-15 | Laxdale Ltd | Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen |
| KR20050083960A (ko) | 2002-11-22 | 2005-08-26 | 닛폰 스이산 가부시키가이샤 | 고도 불포화 지방산, 그 염, 또는 그 에스테르를 함유하는외용 조성물 |
| JP2005179211A (ja) | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
| EP1711173A2 (en) | 2003-12-31 | 2006-10-18 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof |
| WO2005102309A2 (en) | 2004-04-26 | 2005-11-03 | Ltb4 Sweden Ab | In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration |
| AU2005262392A1 (en) | 2004-07-01 | 2006-01-19 | Johnson & Johnson Vision Care, Inc. | Compositions and methods for treating eye disorders and conditions |
| US7666447B2 (en) | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
| US7893106B2 (en) | 2004-11-19 | 2011-02-22 | Martek Biosciences, Corporation | Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same |
| JP5504405B2 (ja) * | 2005-06-10 | 2014-05-28 | 国立大学法人山口大学 | 血管病予防に効果を有する食品組成物 |
| EP3285072B1 (en) | 2006-08-08 | 2020-04-15 | Metabolon, Inc. | Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| US20110105510A1 (en) | 2008-06-17 | 2011-05-05 | Hiroshi Ishikawa | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
| JP2010229099A (ja) * | 2009-03-27 | 2010-10-14 | Mochida Pharmaceut Co Ltd | 脂質異常症の改善または治療薬 |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| CA2972063C (en) * | 2009-05-22 | 2019-12-17 | Mochida Pharmaceutical Co., Ltd. | Self-emulsifying composition of .omega.3 fatty acid |
| CA2690488C (en) | 2010-01-19 | 2013-06-11 | Accucaps Industries Limited | Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof |
| US10154977B2 (en) | 2011-03-25 | 2018-12-18 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory particles |
| US20120264824A1 (en) | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| RU2014119948A (ru) | 2011-10-19 | 2015-11-27 | Дигнити Сайенсиз Лимитед | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ DGLA И/ИЛИ 15-HETrE, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| JP2015500639A (ja) | 2011-11-29 | 2015-01-08 | ディグニティ サイエンシス リミテッド | ２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法 |
| RS57777B1 (sr) | 2012-01-06 | 2018-12-31 | Omthera Pharmaceuticals Inc | Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline |
| US20120264705A1 (en) | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| US20130267598A1 (en) | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| JP6359517B2 (ja) * | 2012-03-30 | 2018-07-18 | サンシリオ アンド カンパニー, インコーポレイテッドSancilio & Company, Inc. | ω−３脂肪酸エステル組成物 |
| WO2013150386A2 (en) | 2012-04-04 | 2013-10-10 | Pronova Biopharma Norge As | Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof |
| DK2858496T3 (da) * | 2012-05-10 | 2023-07-24 | Solutex Na Llc | Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere |
| GB201213484D0 (en) * | 2012-07-30 | 2012-09-12 | Dignity Sciences Ltd | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| WO2015008848A1 (ja) * | 2013-07-18 | 2015-01-22 | 持田製薬株式会社 | ω３脂肪酸の自己乳化組成物 |
| JP2016538288A (ja) * | 2013-11-15 | 2016-12-08 | ディグニティ サイエンシス リミテッド | 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 |
| EP3091959A4 (en) * | 2014-01-10 | 2017-09-20 | Dignity Sciences Limited | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
| MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| US20180008567A1 (en) * | 2015-01-16 | 2018-01-11 | Afimmune Limited | Compositions comprising 15-hepe and methods of using the same |
| MA47141A (fr) * | 2015-05-13 | 2019-11-06 | Ds Biopharma Ltd | Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation |
| ES2851525T3 (es) * | 2015-07-21 | 2021-09-07 | Afimmune Ltd | Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia |
| CA3129008A1 (en) * | 2015-12-18 | 2017-06-22 | Afimmune Limited | Compositions comprising 15-hepe and methods of using the same |
-
2016
- 2016-12-19 CA CA3129008A patent/CA3129008A1/en active Pending
- 2016-12-19 BR BR122023026625-0A patent/BR122023026625A2/pt not_active Application Discontinuation
- 2016-12-19 CN CN201680082030.9A patent/CN108697680A/zh active Pending
- 2016-12-19 EP EP23158607.4A patent/EP4218736A3/en active Pending
- 2016-12-19 US US15/383,889 patent/US9855238B2/en active Active
- 2016-12-19 MX MX2018007390A patent/MX379262B/es unknown
- 2016-12-19 RU RU2020137883A patent/RU2020137883A/ru unknown
- 2016-12-19 KR KR1020237010220A patent/KR20230047501A/ko not_active Ceased
- 2016-12-19 AR ARP160103915A patent/AR107143A1/es not_active Application Discontinuation
- 2016-12-19 KR KR1020187020457A patent/KR20180094516A/ko not_active Ceased
- 2016-12-19 SG SG11201805149XA patent/SG11201805149XA/en unknown
- 2016-12-19 MX MX2021000773A patent/MX394051B/es unknown
- 2016-12-19 RU RU2018126361A patent/RU2737089C2/ru active
- 2016-12-19 NZ NZ744323A patent/NZ744323A/en unknown
- 2016-12-19 IL IL294736A patent/IL294736A/en unknown
- 2016-12-19 AU AU2016370626A patent/AU2016370626B2/en active Active
- 2016-12-19 KR KR1020257027779A patent/KR20250130433A/ko active Pending
- 2016-12-19 ES ES16834282T patent/ES2948444T3/es active Active
- 2016-12-19 WO PCT/IB2016/001878 patent/WO2017103671A1/en not_active Ceased
- 2016-12-19 KR KR1020227008483A patent/KR20220038818A/ko not_active Ceased
- 2016-12-19 IL IL318963A patent/IL318963A/en unknown
- 2016-12-19 KR KR1020247011532A patent/KR20240052856A/ko not_active Ceased
- 2016-12-19 KR KR1020207013456A patent/KR20200055154A/ko not_active Ceased
- 2016-12-19 JP JP2018531629A patent/JP2018537513A/ja active Pending
- 2016-12-19 CA CA3008774A patent/CA3008774C/en active Active
- 2016-12-19 EP EP16834282.2A patent/EP3389647B1/en active Active
- 2016-12-19 CN CN202110567290.8A patent/CN113230244A/zh active Pending
-
2017
- 2017-12-14 US US15/841,363 patent/US10231945B2/en active Active
-
2018
- 2018-06-06 IL IL259846A patent/IL259846A/en unknown
- 2018-06-14 PH PH12018501279A patent/PH12018501279A1/en unknown
- 2018-07-17 ZA ZA2018/04779A patent/ZA201804779B/en unknown
-
2019
- 2019-01-31 US US16/263,486 patent/US20190224154A1/en not_active Abandoned
- 2019-11-27 JP JP2019214063A patent/JP2020063259A/ja active Pending
-
2020
- 2020-11-11 AU AU2020267224A patent/AU2020267224B2/en active Active
-
2021
- 2021-07-15 ZA ZA2021/04969A patent/ZA202104969B/en unknown
- 2021-07-19 JP JP2021118532A patent/JP2021178840A/ja active Pending
-
2022
- 2022-05-20 US US17/750,262 patent/US12274685B2/en active Active
- 2022-12-23 AU AU2022291628A patent/AU2022291628B2/en active Active
-
2023
- 2023-07-21 JP JP2023118782A patent/JP2023153863A/ja active Pending
-
2024
- 2024-11-04 AR ARP240103022A patent/AR134220A2/es unknown
-
2025
- 2025-03-05 AU AU2025201593A patent/AU2025201593A1/en active Pending
- 2025-03-19 US US19/083,602 patent/US20250281442A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020137883A (ru) | Композиции, содержащие 15-hepe, и способы их применения | |
| JP2018537513A5 (https=) | ||
| JP6389190B2 (ja) | 固溶体組成物および慢性炎症における使用 | |
| RU2020123679A (ru) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания | |
| EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| JP2019048843A5 (https=) | ||
| EA201890852A1 (ru) | Соли валбеназина и их полиморфы | |
| Kim et al. | Neuroprotective and therapeutic effect of Cordyceps militaris on ischemia-induced neuronal death and cognitive impairments | |
| JP2018514534A5 (https=) | ||
| RU2018111327A (ru) | Способ ингибирования всасывания и/или повышения выведения липидов с использованием d-псикозы | |
| MX394764B (es) | Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina | |
| EA200870469A1 (ru) | Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение | |
| EP2950821A1 (en) | Compositions and methods for treating chronic inflammation and inflammatory diseases | |
| RU2018136872A (ru) | Композиции, содержащие 15-oh эпк, и способы их применения | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| JP2017536380A (ja) | １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| US20170049840A1 (en) | Compositions containing extracts of curcuma longa and echinacea angustifolia which are useful to reduce peripheral inflammation and pain | |
| JP2018502163A5 (https=) | ||
| HRP20240812T1 (hr) | Oblici doziranja i terapijska primjena l-4-klorokinurenina | |
| JP2018524274A (ja) | １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法 | |
| JP2016514706A5 (https=) | ||
| EA201990883A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| RU2016101152A (ru) | Терапевтические агенты для применения в профилактике и/или лечении гиперкинетических двигательных расстройств | |
| NZ606177A (en) | Compositions for the treatment of actinic keratosis | |
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном |